B. Andrick

发表

Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review.

Tuyet-Trinh N. Truong, Jessie Signorelli, A. Gandhi, 2022, Clinical lymphoma, myeloma & leukemia.

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic

A. Clemmons, C. Sportés, A. Gandhi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia

Frederick Leri, B. Andrick, Lindsay Okubo, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib

L. Bryan, P. R. Somanath, D. DeRemer, 2018, British journal of haematology.

Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins

W. Meng, Lauren A. O'Donnell, B. Andrick, 2015, PloS one.

A Bioinformatics Practicum to Develop Student Understanding of Immunological Rejection of Protein Drugs

W. Meng, Lauren A. O'Donnell, B. Andrick, 2016, American Journal of Pharmaceutical Education.

Current advances in Hodgkin’s lymphoma

J. Vadakara, B. Andrick, Joseph Vadakara, 2019, Chronic diseases and translational medicine.

Antibody Response to Pneumococcal Conjugate Vaccine (PCV13) in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

D. DeRemer, R. Khan, J. Pantin, 2016 .

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma

A. Gandhi, B. Andrick, 2017, The Annals of pharmacotherapy.

Pharmacist value-added to neuro-oncology subspecialty clinics: A pilot study uncovers opportunities for best practices and optimal time utilization

N. T. Gatson, Erika N Leese, Anupama D Mathur, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia

B. Andrick, Dennis Marjoncu, 2020, Journal of the Advanced Practitioner in Oncology.

Cancer patients' experience with a pharmacist‐led oral chemotherapy clinic: A qualitative descriptive study

M. Gionfriddo, Anupama D Mathur, B. Andrick, 2022, Journal of the American College of Clinical Pharmacy.

Impact of a pharmacist-led telehealth oral chemotherapy clinic.

Anupama D Mathur, B. Andrick, Tristan A Maiers, 2022, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy

J. Graham, B. Andrick, Jesse J. Manikowski, 2021, The Annals of pharmacotherapy.

Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey

Stephen Harnicar, G. Riebandt, Shannon M Hough, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The impact of a hematopoietic cellular therapy pharmacist on clinical and humanistic outcomes: A RE-AIM framework analysis.

Laney K. Jones, L. Tusing, J. Lynch, 2022, Transplantation and cellular therapy.